Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nefazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nefazodone SCHEMBL30054492 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL5501519 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL8195097 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL7659683 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL6479060 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL29375893 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL35089 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL27748020 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL9275261 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL27748022 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4097 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20250332164-A1 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-30 | — | — | US | claimed |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | claimed |
| US-20240350483-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2024-10-24 | — | — | US | claimed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| CN-118206634-A | Ligand-regulated protein-protein interaction system | 圣安娜儿童癌症研究中心 | 2024-06-18 | — | — | CN | claimed |
| CN-118196515-A | Zebra fish phenotype identification method | 福建医科大学附属第一医院 | 2024-06-14 | — | — | CN | claimed |
| US-20240041871-A1 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| US-20240024334-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-01-25 | — | — | US | claimed |
| WO-1998021958-A1 | NEFAZODONE: USE IN TREATING POST TRAUMATIC STRESS DISORDER | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998004261-A1 | NEFAZODONE: USE IN MIGRAINE PROPHYLAXIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | claimed |
| EP-0769297-A1 | Use of nefazodone for the manufacture of a medicament for the treatment of panic attack | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-23 | — | — | EP | claimed |
| US-5504086-A | MAXIMIZING ANTIANXIETY, ANTICONVULSANT AND/OR HYPNOTIC EFFECTS; HUMAN CENTRAL NERVOUS SYSTEM; SIDE EFFECT REDUCTION | ELLINWOOD JR EVERETT H (US) | 1996-04-02 | — | — | US | claimed |
| EP-0684816-A1 | 5-HT 2? RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | SAM AMER & CO., INC. (US) | 1995-12-06 | — | — | EP | claimed |
| WO-1994018958-A1 | 5-HT2 RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | SAM AMER & CO., INC. (US) | 1994-09-01 | — | — | WO | claimed |
| US-5266571-A | Treatment of hemorrhoids with 5-HT2 antagonists | VENTRUS BIOSCIENCES, INC. | 1993-11-30 | — | — | US | claimed |
| EP-0337050-A1 | Process and apparatus for the partial or total demineralisation of water | CILLIT WASSERTECHNIK GMBH & CO. (DE) | 1989-10-18 | — | — | EP | claimed |
| EP-0227051-A2 | Heat pump installation with a heat source for heating and distributing of heating and/or sanitary hot water | Gössi, Hans (CH) | 1987-07-01 | — | — | EP | claimed |
| US-4338317-A | Phenoxyethyl-1,2,4,-triazol-3-one antidepressants | MEAD JOHNSON & COMPANY (US) | 1982-07-06 | — | — | US | claimed |